title: Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (S-HPMPC) on simian varicella infection in monkeys.
abstract: (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (S-HPMPC) was able to prevent simian varicella infection in African green monkeys inoculated intratracheally with virus. A dose of 50 mg/S-HPMPC/kg administered intravenously was shown to prevent the development of rash, reduce viremia and protect the monkeys from death. The 50 mg/kg dose was effective when treatments initiated on day 2 post-infection (p.i.) was given as ten daily doses of 5 mg/kg, as 10 mg/kg administered on five days on an alternate-day schedule, as two 25 mg/kg doses given on day 2 and on day 7 p.i., or as a single injection of 50 mg/kg on day 2. The single 50 mg/kg dose was also effective when treatment was delayed until four days p.i., but was ineffective when treatment was delayed until six days p.i. The 50 mg/kg dose was not effective when given orally by gavage. No evidence of toxicity was noted in daily clinical examinations, or in frequent hematology and clinical chemistry tests performed during the clinical evaluation of the infection.
authors.affiliation: Delta Regional Primate Research Center, Tulane University, Covington, LA.
authors.forename: K F
authors.initials: KF
authors.lastname: Soike
authors.forename: J L
authors.initials: JL
authors.lastname: Huang
authors.forename: J Y
authors.initials: JY
authors.lastname: Zhang
authors.forename: R
authors.initials: R
authors.lastname: Bohm
authors.forename: M J
authors.initials: MJ
authors.lastname: Hitchcock
authors.forename: J C
authors.initials: JC
authors.lastname: Martin
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D002644:Chickenpox / Q000188:drug therapy*; D002522:Chlorocebus aethiops; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014645:Herpesvirus 3, Human / Q000187:drug effects* / Q000276:immunology; D007275:Injections, Intravenous; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D014766:Viremia / Q000188:drug therapy
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir